Abstract:More than 2·7 million individuals worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 187 000 have died from the resulting coronavirus disease 2019 (COVID-19) as of April 25, 2020.1WHOCoronavirus disease 2019 (COVID-19) situation report 96.https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200425-sitrep-96-covid-19.pdf?sfvrsn=a33836bb_2Date: April 25, 2020Date accessed: April 26, 2020Google Scholar Despite the common use of immunosuppressive medications, it appears that patients with inflammatory bowel disease (IBD) have a similar risk for COVID-19 to the general population.2SECURE-IBDCOVID-19 in people with inflammatory bowel disease.https://ucalgary.maps.arcgis.com/apps/opsdashboard/index.html#/7f596bdbf4654e19a3a3cf13b6e597deDate accessed: April 26, 2020Google Scholar The management of IBD during and after the pandemic is challenging. The main concerns from a clinician's perspective are the risk for COVID-19 in patients with IBD (especially in those taking immunosuppressive medications or with malnutrition), timely follow-up and monitoring of disease, choice of and change in medical and surgical therapy, feasibility and availability of endoscopic assessment, and protection of health-care providers against SARS-CoV-2 infection.3Mao R Liang J Shen J et al.Implications of COVID-19 for patients with pre-existing digestive diseases.Lancet Gastroenterol Hepatol. 2020; 5: 426-428Summary Full Text Full Text PDF PubMed Scopus (247) Google Scholar, 4Yang H Zhu LR Tian D Inflammatory Bowel Disease GroupChinese Society of GastroenterologyChinese Medical AssociationManagement of patients with inflammatory bowel disease during epidemic of 2019 novel coronavirus pneumonia.Chin J Dig. 2020; 40 (in Chinese).: E001Google Scholar, 5International Organisation for the study of IBDIOIBD update on COVID19 for patients with Crohn's disease and ulcerative colitis.https://www.ioibd.org/ioibd-update-on-covid19-for-patients-withcrohns-disease-and-ulcerative-colitisDate: April 23, 2020Date accessed: April 23, 2020Google Scholar, 6Rubin DT Abreu MT Rai V Siegel CA Management of patients with Crohn's disease and ulcerative colitis during the COVID-19 pandemic: results of an international meeting.Gastroenterology. 2020; (published online April 6.)DOI:10.1053/j.gastro.2020.04.002Summary Full Text Full Text PDF Scopus (170) Google Scholar, 7Rubin DT Feuerstein JD Wang AY Cohen RD AGA clinical practice update on management of inflammatory bowel disease during the covid-19 pandemic: expert commentary.Gastroenterology. 2020; (published online April 10.)DOI:10.1053/j.gastro.2020.04.012Summary Full Text Full Text PDF Scopus (179) Google Scholar Additional concerns have been raised from the patients' perspective, including medical, psychosocial, and financial factors. Therefore, we did a survey involving patients with IBD to analyse their feedback on their care during the early and late phases of the COVID-19 outbreak in China. The anonymous questionnaire was designed by clinicians, registered nurses, and patient representatives and was posted on the China Crohn's and Colitis Foundation's patient portal. 2277 participants completed the survey. 880 (39%) were women and 1397 (61%) men; 1639 (72%) had Crohn's disease and 555 (24%) had ulcerative colitis. 111 (5%) respondents were from Hubei province. Of the 2277 respondents, 1134 (50%) were employed full or part time. Most (934 [82%] of 1134) had to work at home during the pandemic and 443 (39%) reported reduced income (appendix). More than 50% of the respondents reported some degree of mood changes, with the peak of the frequency of moderate-to-severe psychological change in the middle of the outbreak in China—ie, mid-February, 2020. Many (1331 [58%] of 2277) respondents were worried about the risk for SARS-CoV-2 infection for themselves and their family and more than half (1184 [52%]) were concerned about the difficulty in seeing physicians (appendix). Almost three-quarters of patients (1691 [74%]) reported that their disease state was stable during the initial outbreak (from January to March, 2020) and 1842 (81%) reported that their disease remained stable in the later phase (ie, mid-April, 2020). 137 (6%) patients were admitted for IBD flares and 23 (1%) had surgery. 639 (28%) patients used telemedicine—of whom 487 (76%) sought help from IBD health-care providers online—and 847 (37%) of 2277 patients had face-to-face visits. Most patients (1744 [77%]) did not change IBD medications during the outbreak. Of the 533 patients with a change in medications, the main reasons for the change were recommendations from treating physicians (157 [30%]), being unable to receive intravenous infusions (151 [28%]), and the availability of physicians or facilities (148 [28%]). Most respondents (1606 [71%] of 2277) were still able to obtain oral medications online (1125 [49%]) or from hospital pharmacies as before (481 [21%]). By mid-April, 2020, most (1628 [71%]) were able to obtain oral medicines from their hospital pharmacies as before (appendix). The COVID-19 pandemic has posed challenges to every aspect of respondents' lives. Measures to curtail the virus, such as shelter-in-place, government mandates for postponing elective procedures, restriction of transportation, and the reassignment of gastroenterologists or IBD health-care providers, can interfere with routine or emergent care. Most patients with IBD experienced stable disease during the early and current phases of the outbreak and those individuals did not have to change their medications. Our survey data suggest that the impact of the COVID-19 outbreak on medical management of IBD was largely related to logistics. Restructuring IBD care, such as personnel reassignment, infusion service availability, drug delivery, and telemedicine, have been proposed as being important for IBD management during such a pandemic.8Allocca M Fiorino G Furfaro F et al.Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic.Clin Gastroenterol Hepatol. 2020; (published online April 15.)DOI:10.1016/j.cgh.2020.04.028Summary Full Text Full Text PDF PubMed Scopus (40) Google Scholar Our survey shows that a quarter of patients sought care via telemedicine with their IBD physicians. There was also increased use of online delivery of oral medications. Mental health issues have been reported by both patients and health-care providers during the outbreak.9Percudani M Corradin M Moreno M Indelicato A Vita A Mental health services in Lombardy during COVID-19 outbreak.Psychiatry Res. 2020; 288112980Crossref PubMed Scopus (105) Google Scholar, 10Zhang WR Wang K Yin L et al.Mental health and psychosocial problems of medical health workers during the COVID-19 epidemic in China.Psychother Psychosom. 2020; (published online April 9.)DOI:10.1159/000507639Crossref Scopus (985) Google Scholar Mental health issues are particularly important in patients with diseases of long duration, such as IBD. Our survey suggests that although patients' moods were affected by concerns about psychosocial and economic issues, their disease course was not affected. Respondents were concerned about the risk of infection and worried about access to health care. More than 50% of respondents had mood changes and their mood changes appeared to improve as the pandemic trend was flattening. More than 80% of employed respondents had to work from home and 40% of the respondents reported a reduced income. The financial impact can be long lasting, which could affect the affordability of and adherence to medical care. This could eventually alter disease outcomes. The results from this large survey suggest that the COVID-19 pandemic affects patients with IBD medically, psychosocially, and financially. Most respondents' disease remained stable. Respondents using maintenance therapy and those requiring medication adjustments because of disease flares often met logistical challenges. The availability of telemedicine and online drug delivery services might have eased some of the burden. Psychosocial and economic effects of the pandemic on IBD care are common. The long-lasting effects will need to be studied over time. FAF has served as a consultant for Bristol-Myers Squibb, Braintree Labs, Gilead, GlaxoSmithKline, Innovation Pharmaceuticals, Janssen, Pfizer, and Sebela, and sits on a data safety monitoring board for Lilly and Theravance. CNB has served on advisory boards for AbbVie Canada, Roche Canada, Janssen Canada, Takeda Canada, and Pfizer Canada; has been a consultant for Mylan Pharmaceuticals; and has received educational grants from AbbVie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada; and acted as a speaker for Janssen Canada, AbbVie Canada, Medtronic Canada, and Takeda Canada. BS has served as a consultant and speaker for AbbVie, Janssen, and Takeda. YC, SH, HW, J-JZ, and RPK declare no competing interests. The authors are grateful to support from surveyed patients. The study was approved by the ethics committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China). YC, SH, and HW contributed equally to this Comment. Download .pdf (.43 MB) Help with pdf files Supplementary appendix

Abstract:A number of published papers have investigated the relation between atrial fibrillation (AF) and clinical outcomes of patients with coronavirus disease 2019 (COVID-19). However, the conclusions drawn from previous studies are not consistent. For instance, some studies observed that AF was significantly associated with an increased risk of mortality among COVID-19 patients,1Peltzer B Manocha KK Ying X Kirzner J Ip JE Thomas G Liu CF Markowitz SM Lerman BB Safford MM Goyal P Cheung JW. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19.J Cardiovasc Electrophysiol. 2020; 31: 3077-3085Crossref PubMed Scopus (63) Google Scholar, 2Reilev M Kristensen KB Pottegard A Lund LC Hallas J Ernst MT Christiansen CF Sorensen HT Johansen NB Brun NC Voldstedlund M Stovring H Thomsen MK Christensen S Gubbels S Krause TG Molbak K Thomsen RW. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort.Int J Epidemiol. 2020; 49: 1468-1481Crossref PubMed Scopus (187) Google Scholar, 3Rodilla E Saura A Jimenez I Mendizabal A Pineda-Cantero A Lorenzo-Hernandez E Fidalgo-Montero MDP Lopez-Cuervo JF Gil-Sanchez R Rabadan-Pejenaute E Abella-Vazquez L Giner-Galvan V Solis-Marquinez MN Boixeda R Pena-Fernandez A Carrasco-Sanchez FJ Gonzalez-Moraleja J Torres-Pena JD Guisado-Espartero ME Escobar-Sevilla J Guzman-Garcia M Martin-Escalante MD Martinez-Gonzalez AL Casas-Rojo JM Gomez-Huelgas R. Association of hypertension with all-cause mortality among hospitalized patients with COVID-19.J Clin Med. 2020; 9https://doi.org/10.3390/jcm9103136Crossref PubMed Scopus (56) Google Scholar while several other studies reported opposite results that there was no significant relation between AF and unfavorable outcomes of COVID-19 patients.4Izurieta HS Graham DJ Jiao Y Hu M Lu Y Wu Y Chillarige Y Wernecke M Menis M Pratt D Kelman J Forshee R. Natural history of COVID-19: risk factors for hospitalizations and deaths among >26 million U.S. Medicare beneficiaries.J Infect Dis. 2020; https://doi.org/10.1093/infdis/jiaa767Crossref Scopus (45) Google Scholar, 5Lala A Johnson KW Januzzi JL Russak AJ Paranjpe I Richter F Zhao S Somani S Van Vleck T Vaid A Chaudhry F De Freitas JK Fayad ZA Pinney SP Levin M Charney A Bagiella E Narula J Glicksberg BS Nadkarni G Mancini DM Fuster V Mount Sinai CIC Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection.J Am Coll Cardiol. 2020; 76: 533-546Crossref PubMed Scopus (495) Google Scholar, 6van Gerwen M Alsen M Little C Barlow J Genden E Naymagon L Tremblay D. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study.J Med Virol. 2021; 93: 907-915Crossref PubMed Scopus (76) Google Scholar Several confounding factors such as gender, age and pre-existing medical disorders (diabetes, hypertension, autoimmune diseases, chronic kidney disease, and chronic obstructive pulmonary disease, etc.) have been reported to significantly influence the clinical outcomes of COVID-19 patients,7Barek MA Aziz MA Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases.Heliyon. 2020; 6: e05684Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar, 8Biswas M Rahaman S Biswas TK Haque Z Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 Patients: a systematic review and meta-analysis.Intervirology. 2020; : 1-12PubMed Google Scholar, 9Liang X Shi L Wang Y Xiao W Duan G Yang H Wang Y. The association of hypertension with the severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates.J Infect. 2020; 81: e44-e47Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar, 10Liang X Xu J Xiao W Shi L Yang H. The association of diabetes with COVID-19 disease severity: evidence from adjusted effect estimates.Hormones. 2020; https://doi.org/10.1007/s42000-020-00259-xCrossref PubMed Scopus (15) Google Scholar, 11Xiao W Xu J Liang X Shi L Zhang P Wang Y Yang H. Relationship between chronic kidney disease and adverse outcomes of coronavirus disease 2019: a meta-analysis based on adjusted risk estimates.Int Urol Nephrol. 2021; https://doi.org/10.1007/s11255-020-02748-9Crossref Scopus (3) Google Scholar, 12Yang H Xu J Liang X Shi L Wang Y. Autoimmune diseases are independently associated with COVID-19 severity: evidence based on adjusted effect estimates.J Infect. 2020; https://doi.org/10.1016/j.jinf.2020.12.025Abstract Full Text Full Text PDF Scopus (16) Google Scholar, 13Xiao WW Xu J Shi L Wang YD Yang HY. Is chronic obstructive pulmonary disease an independent predictor for adverse outcomes in coronavirus disease 2019 patients?.Eur Rev Med Pharmacol Sci. 2020; 24: 11421-11427PubMed Google Scholar suggesting that these factors might have significant impacts on the relation between AF and unfavorable outcomes of COVID-19 patients. In this meta-analysis, the pooled effect size was estimated on the basis of adjusted effect estimates reported in published papers. We systematically searched PubMed, Web of Science, and EMBASE databases to identify all potential documents published between January 1, 2020 and December 24, 2020, using the following keywords and terms: “severe acute respiratory syndrome coronavirus-2” or “SARS-CoV-2” or “coronavirus disease 2019” or “COVID-19” or “2019 novel coronavirus” or “2019-nCoV” and “atrial fibrillation” and “severity” or “severe” or “critical” or “mortality” or “death” or “fatality” or “intensive care unit” or “mechanical ventilation”. Studies were eligibly included if they met the following criteria: (1) studies reporting laboratory-confirmed COVID-19 patients; (2) articles should be peer-reviewed; (3) articles should be published in English; (4) the adjusted effect estimate on the relation between AF and unfavorable outcomes of COVID-19 patients are available. Accordingly, studies were excluded if they were: (1) repeated studies, review papers, comments, errata, protocols and case reports; (2) articles reporting crude effect size; (3) articles with insufficient data; (4) in vitro studies or animal studies. Two investigators independently extracted the basic characteristics including name of authors, country and/or region, number of cases, percentage of male, age (mean ± standard deviation or median (interquartile range), study design, adjusted effect size and outcomes. In case of disagreement, a third investigator was consulted and made a final decision. Statistical analysis was carried out using Stata 12.1 software. I2 statistic and Cochran's Q test were adopted in the assessment of heterogeneity among the included studies. The pooled effect size and 95% confidence interval (CI) were calculated to estimate the relation between AF and unfavorable outcomes of COVID-19 patients. A fixed-effects analysis was conducted if there was no heterogeneity (I2 < 50% or p > 0.1), otherwise, a random-effects analysis was carried out (I2 > 50% or p < 0.1). Leave-one-out sensitivity analysis was performed to assess the stability of our results. Publication bias was evaluated by Begg's rank correlation test and Egger's linear regression test. Subgroup analysis and meta-regression analysis were also performed to probe the source of heterogeneity. A p-value < 0.05 was deemed statistically significant. Nine hundred and sixteen potentially relevant studies were screened according to the inclusion and exclusion criteria. Finally, 23 studies with 108,745 COVID-19 patients1Peltzer B Manocha KK Ying X Kirzner J Ip JE Thomas G Liu CF Markowitz SM Lerman BB Safford MM Goyal P Cheung JW. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19.J Cardiovasc Electrophysiol. 2020; 31: 3077-3085Crossref PubMed Scopus (63) Google Scholar, 2Reilev M Kristensen KB Pottegard A Lund LC Hallas J Ernst MT Christiansen CF Sorensen HT Johansen NB Brun NC Voldstedlund M Stovring H Thomsen MK Christensen S Gubbels S Krause TG Molbak K Thomsen RW. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort.Int J Epidemiol. 2020; 49: 1468-1481Crossref PubMed Scopus (187) Google Scholar, 3Rodilla E Saura A Jimenez I Mendizabal A Pineda-Cantero A Lorenzo-Hernandez E Fidalgo-Montero MDP Lopez-Cuervo JF Gil-Sanchez R Rabadan-Pejenaute E Abella-Vazquez L Giner-Galvan V Solis-Marquinez MN Boixeda R Pena-Fernandez A Carrasco-Sanchez FJ Gonzalez-Moraleja J Torres-Pena JD Guisado-Espartero ME Escobar-Sevilla J Guzman-Garcia M Martin-Escalante MD Martinez-Gonzalez AL Casas-Rojo JM Gomez-Huelgas R. Association of hypertension with all-cause mortality among hospitalized patients with COVID-19.J Clin Med. 2020; 9https://doi.org/10.3390/jcm9103136Crossref PubMed Scopus (56) Google Scholar, 4Izurieta HS Graham DJ Jiao Y Hu M Lu Y Wu Y Chillarige Y Wernecke M Menis M Pratt D Kelman J Forshee R. Natural history of COVID-19: risk factors for hospitalizations and deaths among >26 million U.S. Medicare beneficiaries.J Infect Dis. 2020; https://doi.org/10.1093/infdis/jiaa767Crossref Scopus (45) Google Scholar, 5Lala A Johnson KW Januzzi JL Russak AJ Paranjpe I Richter F Zhao S Somani S Van Vleck T Vaid A Chaudhry F De Freitas JK Fayad ZA Pinney SP Levin M Charney A Bagiella E Narula J Glicksberg BS Nadkarni G Mancini DM Fuster V Mount Sinai CIC Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection.J Am Coll Cardiol. 2020; 76: 533-546Crossref PubMed Scopus (495) Google Scholar, 6van Gerwen M Alsen M Little C Barlow J Genden E Naymagon L Tremblay D. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study.J Med Virol. 2021; 93: 907-915Crossref PubMed Scopus (76) Google Scholar,14Atkins JL Masoli JAH Delgado J Pilling LC Kuo CL Kuchel GA Melzer D. Preexisting comorbidities predicting COVID-19 and mortality in the UK biobank community cohort.J Gerontol A Biol Sci Med Sci. 2020; 75: 2224-2230Crossref PubMed Scopus (302) Google Scholar, 15Hippisley-Cox J Tan PS Coupland C. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.Heart. 2020; https://doi.org/10.1136/heartjnl-2020-318312Crossref Scopus (8) Google Scholar, 16Peterson E Lo KB DeJoy R Salacup G Pelayo J Bhargav R Gul F Albano J Azmaiparashvili Z Amanullah A Patarroyo-Aponte G. The relationship between coronary artery disease and clinical outcomes in COVID-19: a single-center retrospective analysis.Coron Artery Dis. 2020; https://doi.org/10.1097/MCA.0000000000000934Crossref PubMed Scopus (23) Google Scholar, 17Perez-Guzman PN Daunt A Mukherjee S Crook P Forlano R Kont MD Lochen A Vollmer M Middleton P Judge R Harlow C Soubieres A Cooke G White PJ Hallett TB Aylin P Ferguson N Hauck K Thursz MR Nayagam S. Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study.Clin Infect Dis. 2020; https://doi.org/10.1093/cid/ciaa1091Crossref Scopus (43) Google Scholar, 18Elias P Poterucha TJ Jain SS Sayer G Raikhelkar J Fried J Clerkin K Griffin J DeFilippis EM Gupta A Lawlor M Madhavan M Rosenblum H Roth ZB Natarajan K Hripcsak G Perotte A Wan EY Saluja A Dizon J Ehlert F Morrow JP Yarmohammadi H Kumaraiah D Redfors B Gavin N Kirtane A Rabbani L Burkhoff D Moses J Schwartz A Leon M Uriel N. The prognostic value of electrocardiogram at presentation to emergency department in patients with COVID-19.Mayo Clin Proc. 2020; 95: 2099-2109Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar, 19Rodriguez-Molinero A Galvez-Barron C Minarro A Macho O Lopez GF Robles MT Dapena MD Martinez S Mila Rafols N Monaco EE Hidalgo Garcia A CSAPG C-RGoAssociation between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients.PloS one. 2020; 15e0239571Crossref PubMed Scopus (40) Google Scholar, 20Clift AK Coupland CAC Keogh RH Diaz-Ordaz K Williamson E Harrison EM Hayward A Hemingway H Horby P Mehta N Benger J Khunti K Spiegelhalter D Sheikh A Valabhji J Lyons RA Robson J Semple MG Kee F Johnson P Jebb S Williams T Hippisley-Cox J. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study.Bmj. 2020; 371: m3731Crossref PubMed Scopus (364) Google Scholar, 21Alvarez-Garcia J Lee S Gupta A Cagliostro M Joshi AA Rivas-Lasarte M Contreras J Mitter SS LaRocca G Tlachi P Brunjes D Glicksberg BS Levin MA Nadkarni G Fayad Z Fuster V Mancini D Lala A. Prognostic impact of prior heart failure in patients hospitalized with COVID-19.J Am Coll Cardiol. 2020; 76: 2334-2348Crossref PubMed Scopus (125) Google Scholar, 22Tang O Bigelow BF Sheikh F Peters M Zenilman JM Bennett R Katz MJ. Outcomes of nursing home COVID-19 patients by initial symptoms and comorbidity: results of universal testing of 1970 residents.J Am Med Dir Assoc. 2020; 21 (e1761): 1767-1773Abstract Full Text Full Text PDF PubMed Scopus (30) Google Scholar, 23Shah C Grando DJ Rainess RA Ayad L Gobran E Benson P Neblett MT Nookala V. Factors associated with increased mortality in hospitalized COVID-19 patients.Ann Med Surg (Lond). 2020; 60: 308-313Crossref PubMed Scopus (11) Google Scholar, 24Tomasoni D Inciardi RM Lombardi CM Tedino C Agostoni P Ameri P Barbieri L Bellasi A Camporotondo R Canale C Carubelli V Carugo S Catagnano F Dalla Vecchia LA Danzi GB Di Pasquale M Gaudenzi M Giovinazzo S Gnecchi M Iorio A La Rovere MT Leonardi S Maccagni G Mapelli M Margonato D Merlo M Monzo L Mortara A Nuzzi V Piepoli M Porto I Pozzi A Sarullo F Sinagra G Volterrani M Zaccone G Guazzi M Senni M Metra M Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.Eur J Heart Fail. 2020; https://doi.org/10.1002/ejhf.2052Crossref Scopus (90) Google Scholar, 25Polverino F Stern DA Ruocco G Balestro E Bassetti M Candelli M Cirillo B Contoli M Corsico A D'Amico F D'Elia E Falco G Gasparini S Guerra S Harari S Kraft M Mennella L Papi A Parrella R Pelosi P Poletti V Polverino M Tana C Terribile R Woods JC Di Marco F Martinez FD Comorbidities, cardiovascular therapies, and COVID-19 mortality: a nationwide, Italian Observational Study (ItaliCO).Front Cardiovasc Med. 2020; 7585866Crossref PubMed Scopus (57) Google Scholar, 26Loffi M Piccolo R Regazzoni V Di Tano G Moschini L Robba D Quinzani F Esposito G Franzone A Danzi GB. Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection.Open heart. 2020; 7https://doi.org/10.1136/openhrt-2020-001428Crossref PubMed Scopus (18) Google Scholar, 27Canevelli M Palmieri L Raparelli V Lo Noce C Colaizzo E Tiple D Vaianella L Vanacore N Brusaferro S Onder G Italian National Institute of Health C-MGPrevalence and clinical correlates of dementia among COVID-19-related deaths in Italy.Alzheimers Dement (Amst). 2020; 12: e12114PubMed Google Scholar, 28Rossi L Malagoli A Biagi A Zanni A Sticozzi C Comastri G Pannone L Gandolfi S Vergara P Villani GQ. Renin-angiotensin system inhibitors and mortality in patients with COVID-19.Infection. 2020; https://doi.org/10.1007/s15010-020-01550-0Crossref Scopus (15) Google Scholar, 29Gue YX Tennyson M Gao J Ren S Kanji R Gorog DA. Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19.Sci Rep. 2020; 10: 21379Crossref PubMed Scopus (26) Google Scholar, 30Lano G Braconnier A Bataille S Cavaille G Moussi-Frances J Gondouin B Bindi P Nakhla M Mansour J Halin P Levy B Canivet E Gaha K Kazes I Noel N Wynckel A Debrumetz A Jourde-Chiche N Moal V Vial R Scarfogliere V Bobot M Gully M Legris T Pelletier M Sallee M Burtey S Brunet P Robert T Rieu P. Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort.Clin Kidney J. 2020; 13: 878-888Crossref PubMed Google Scholar were eligibly included in the present quantitative meta-analysis. The study characteristics are summarized in Table 1. Ten studies came from United States of America (USA) and 13 studies were from Europe (5 from United Kingdom, 4 from Italy, 2 from Spain and 1 each from Denmark and France). Results of our meta-analysis indicated that AF was significantly associated with an increased risk of unfavorable outcomes among COVID-19 patients (pooled effect size = 1.14, 95% CI: 1.03 to 1.26, p = 0.01; I2 = 63.9%, random-effects analysis; Figure 1). When the clinical outcomes were limited to death, there was still a significant relation between AF and COVID-19 mortality (pooled effect size = 1.13, 95% CI: 1.02 to 1.25). Subgroup analysis by effect estimate showed consistent results (pooled effect size = 1.12, 95% CI: 1.04 to 1.21 for hazard ratio (HR)-reported studies and pooled effect size = 1.18, 95% CI: 1.02 to 1.37 for odds ratio (OR)-reported studies). Inconsistent results were observed in the subgroup analyses by sample size (pooled effect size = 1.14, 95% CI: 1.02 to 1.27 for ≥ 1,000 cases and pooled effect size = 1.12, 95% CI: 0.87 to 1.44 for < 1,000 cases), age (pooled effect size = 1.18, 95% CI: 1.06 to 1.31 for < 70 years old and pooled effect size = 1.06, 95% CI: 0.87 to 1.29 for ≥ 70 years old), percentage of male (pooled effect size = 1.26, 95% CI: 1.06 to 1.51 for ≥ 60% and pooled effect size = 1.09, 95% CI: 0.97 to 1.22 for < 60%) and region (pooled effect size = 1.21, 95% CI: 1.08 to 1.35 for Europe and pooled effect size = 1.06, 95% CI: 0.90 to 1.24 for USA). We observed no significant relation between AF and unfavorable outcomes among COVID-19 patients in the subgroup analysis of study design (pooled effect size = 1.08, 95% CI: 0.97 to 1.22 for retrospective study, pooled effect size = 1.27, 95% CI: 0.95 to 1.70 for observational cohort study and pooled effect size = 1.34, 95% CI: 0.92 to 1.96 for the others). Sensitivity analysis showed that our results were stable and reliable since omitting each study one by one had no obvious effects on the overall effect size (Figure 1). There was no obvious publication bias assessed by Begg's test (p = 0.428, Figure 1) and Egger's test (p = 0.081, Figure 1). Meta-regression analysis exhibited that the tested variables such as sample size, age, percentage of male, region, study design, and effect estimate might not be the source of heterogeneity (data not shown).Table 1Main characteristics of the studies included in this meta-analysisAuthorCountryCasesMale (%)Age§Study designAdjusted-effect size (95% CI)Lala AUSA273659.6%66.4Retrospective studyOR: 1.08 (0.81-1.44)Atkins JLUK50761.3%74.3±4.5UK biobank cohortOR: 1.63 (0.98-2.71)van Gerwen MUSA370355.3%56.8±18.2Retrospective studyOR: 1.19 (0.87-1.62)Hippisley-Cox JUK1948648.1%62.18±20.84Prospective studyHR: 0.87 (0.55-1.39)Peterson EUSA35551%66.21±14.21Retrospective studyOR: 0.475 (0.190-1.188)Perez-Guzman PNUK61462.2%69 (25)Retrospective studyOR: 1.25 (0.73-2.13)Reilev MDenmark1112242.2%48 (33-62)Population-based studyOR: 1.6 (1.2-2.0)Rodilla ESpain1222657.4%67.5±16.1Retrospective studyOR: 1.2 (1.01-1.33)Elias PUSA125854%61.6±18.4Retrospective studyOR: 2.54 (1.05-6.2)Peltzer BUSA105362.3%62±17Retrospective studyOR: 2.16 (1.33-3.52)Rodriguez-Molinero ASpain41856.9%65.4±16.6Observational cohort studyOR: 1.86 (0.86-4.02)Clift AKUK1077655.3%69.63±17.91Observational cohort studyHR: 1.18 (1.04-1.34)HR: 1.11 (1.00-1.24)Alvarez-Garcia JUSA634955.1%63.5±18Retrospective studyHR: 0.91 (0.63-1.31)Tang OUSA75239.9%71.16±51.68Retrospective studyHR: 0.86 (0.57-1.30)Shah CUSA48756.1%68.42±16.70Retrospective studyOR: 0.91 (0.50-1.65)Tomasoni DItaly69269.5%67.4±13.2Retrospective studyHR: 1.27 (0.73-2.23)Polverino FUSA317968.3%69.0 (57-78)Retrospective studyOR: 0.97 (0.69-1.36)Loffi MItaly125263.7%64.7±15.5Retrospective studyHR: 1.09 (0.75-1.58)Canevelli MItaly262167.6%78.16±10.51Retrospective studyOR: 0.99 (0.72-1.37)Rossi LItaly59066.1%76.2 (68.2-82.6)Retrospective studyHR: 1.390 (0.925-1.885)Gue YXUK48638.7%73.42±15.97Retrospective studyOR: 0.49 (0.35-1.58)Izurieta HSUSA2796148.8%79.07±10.15Retrospective studyOR: 0.97 (0.92-1.01)Lano GFrance12265%73.5 (64.2-81.2)Observational cohort studyOR: 1.838 (0.751-4.481)Note: § indicates the values are presented as mean ± standard deviation (SD) or median (interquartile range, IQR); CI, confidence interval; HR, hazard ratio; OR, odds ratio; UK, the United Kingdom; USA, the United States of America. Open table in a new tab Note: § indicates the values are presented as mean ± standard deviation (SD) or median (interquartile range, IQR); CI, confidence interval; HR, hazard ratio; OR, odds ratio; UK, the United Kingdom; USA, the United States of America. Limitations: (1) All the included studies came from USA and Europe. (2) Because medications for COVID-19 were not clearly reported in most of the included studies, we did not address the effects of these factors on the relation between AF and unfavorable outcomes of COVID-19 patients. (3) The adjusted risk factors are variable across the included studies. (4) Most of the studies are retrospective, further meta-analyses based on prospective studies with large sample size are warranted to verify our findings when more data are available. In conclusion, our study demonstrates that AF was significantly associated with an increased risk of unfavorable outcomes among COVID-19 patients, especially for death. Yadong Wang and Haiyan Yang designed the study. Xuan Liang and Jie Xu performed literature search. Haiyan Yang and Xuan Liang performed data extraction. Xuan Liang, Haiyan Yang, Jie Xu and Hongjie Hou performed statistical analyses. Haiyan Yang, Xuan Liang and Yadong Wang wrote and reviewed the manuscript. All the authors approved the final version of the manuscript. The authors declare that they have no any potential conflict of interest regarding this submitted manuscript. We would like to thank Li Shi, Ying Wang, Peihua Zhang, Yang Li, Jian Wu and Wenwei Xiao (All are from Department of Epidemiology, School of Public Health, Zhengzhou University) for their kind help in searching articles and collecting data, and valuable suggestions for data analysis.

Meta‐analysis: Post‐COVID‐19 functional dyspepsia and irritable bowel syndrome

Impacts of the COVID‐19 pandemic on functional dyspepsia and irritable bowel syndrome: A population‐based survey

Patterns of Care for Inflammatory Bowel Disease in China During the COVID-19 Pandemic.

P1179 Long-term impact of COVID-19 on the disease course of IBD: a meta-analysis

The Prevalence of Irritable Bowel Syndrome after Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Their Association: A Systematic Review and Meta-Analysis of Observational Studies

Post‐infection functional gastrointestinal disorders following coronavirus disease‐19: A case–control study

Overlap of functional dyspepsia and irritable bowel syndrome by revised Rome IV criteria: meta-analysis

Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis

Post-infection functional gastrointestinal disorders following coronavirus disease-19: a prospective follow-up cohort study

Practice Patterns of Medical Management of Inflammatory Bowel Disease During Pandemic of COVID-19: A Global Survey of Health Care Providers

A Meta-Analysis on the Association Between Peptic Ulcer Disease and COVID-19 Severity

Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis

Meta-Analysis of Atrial Fibrillation in Patients With COVID-19

The Physiological and Psychological Effects of Cognitive Behavior Therapy on Patients with Inflammatory Bowel Disease Before COVID-19: a Systematic Review

Incidence of constipation and associated factors in the period of lockdown during COVID-19 pandemic: protocol for a systematic review and meta-analysis

Comparison of Laboratory Characteristics of Gastrointestinal Symptoms and Nongastrointestinal Symptoms in Patients Infected with COVID-19: a Systematic Review and Meta-Analysis

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Intestinal inflammation and permeability in patients recovered from SARS-CoV-2 infection.

P899 Inflammatory Bowel Disease Patients Show More Recognizable Digestive Symptoms of COVID-19: A Questionnaire Study

Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis

Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis